Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy
Authors: Nongnuch Sirachainan
Issarang Nuchprayoon
Pattra Thanarattanakorn
Samart Pakakasama
Apasri Lusawat
Anannit Visudibhan
Mantana Dhanachai
Noppadol Larbcharoensub
Jiraporn Amornfa
Kanchana Shotelersuk
Kamornwan Katanyuwong
Saipin Tangkaratt
Suradej Hongeng
Mahidol University
Chulalongkorn University
Chiang Mai University
Prasat Neurological Institute
National Cancer Institute Thailand
Keywords: Medicine;Neuroscience
Issue Date: 1-Apr-2011
Citation: Journal of Clinical Neuroscience. Vol.18, No.4 (2011), 515-519
Abstract: Medulloblastoma is the most common malignant brain tumor in children. Post-surgical craniospinal irradiation (CSI; 30-36 Gy) plus local boost radiation therapy (RT; 54-56 Gy) is a standard treatment for children with medulloblastoma who are over 3 years old, resulting in a 5-year overall survival (OS) rate of 46% to 65% in average-risk patients and 50% in high-risk patients. The addition of chemotherapy has the benefit of reducing complications from radiation and improving the OS rate. Using this approach, the estimated 5-year OS rates for patients with average- and high-risk medulloblastomas treated with different protocols are 65% to 85% and 16% to 70%, respectively. In this study, we determined the outcome of patients with average- and high-risk medulloblastomas treated with reduced dosage CSI and chemotherapy with an oral etoposide-based regimen. The study included 49 patients, with a mean age of 7.7 ± 3.4 years. Twenty-six patients (53%) were classified as average-risk and 23 patients (47%) as high-risk. In the average-risk group, the 5-year progression free survival (PFS) rate was 62.9% ± 10% and the 5-year OS rate was 70.4% ± 9.5%. In the high-risk group the 5-year PFS rate was 48.9% ± 13% and the 5-year OS rate was 49.7% ± 13%. In the average-risk group, patients who received CSI of either 24 Gy (n = 20) or 36 Gy (n = 9) showed no difference in their 5-year PFS and OS rates. We found that patients who were ≤10 years old and patients who were female had a significantly better 5-year PFS rate. © 2010 Elsevier Ltd. All rights reserved.
ISSN: 09675868
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.